BSE Live
Jan 16, 16:01Prev. Close
1180.25
Open Price
1171.55
Bid Price (Qty.)
1172.30 (1)
Offer Price (Qty.)
1179.00 (1)
NSE Live
Jan 16, 15:50Prev. Close
1180.10
Open Price
1174.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1172.70 (585)
| Key Financial Ratios of Aurobindo Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 52.01 | 40.24 | 17.04 | -1.46 | 20.63 | |
| Diluted EPS (Rs.) | 51.97 | 40.20 | 17.02 | -1.46 | 18.56 | |
| Cash EPS (Rs.) | 60.33 | 46.59 | 22.92 | 3.45 | 24.69 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 183.55 | 137.65 | 100.93 | 85.65 | 88.27 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 183.55 | 137.65 | 100.93 | 85.65 | 88.27 | |
| Dividend / Share(Rs.) | 3.00 | 3.00 | 1.50 | 1.00 | 2.00 | |
| Revenue from Operations/Share (Rs.) | 277.23 | 243.94 | 186.30 | 147.08 | 141.98 | |
| PBDIT/Share (Rs.) | 79.37 | 68.41 | 33.81 | 20.36 | 34.84 | |
| PBIT/Share (Rs.) | 70.98 | 62.03 | 27.93 | 15.45 | 30.55 | |
| PBT/Share (Rs.) | 66.45 | 52.13 | 19.34 | -4.73 | 27.67 | |
| Net Profit/Share (Rs.) | 51.93 | 40.21 | 17.03 | -1.46 | 20.40 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 28.63 | 28.04 | 18.14 | 13.84 | 24.53 | |
| PBIT Margin (%) | 25.60 | 25.43 | 14.98 | 10.50 | 21.51 | |
| PBT Margin (%) | 23.96 | 21.36 | 10.37 | -3.21 | 19.48 | |
| Net Profit Margin (%) | 18.73 | 16.48 | 9.14 | -0.99 | 14.36 | |
| Return on Networth / Equity (%) | 28.29 | 29.21 | 16.87 | -1.70 | 23.10 | |
| Return on Capital Employed (%) | 33.00 | 34.38 | 20.04 | 13.48 | 28.05 | |
| Return on Assets (%) | 14.82 | 13.66 | 7.26 | -0.71 | 10.16 | |
| Total Debt/Equity (X) | 0.54 | 0.70 | 0.94 | 0.98 | 0.66 | |
| Asset Turnover Ratio (%) | 0.86 | 0.92 | 0.85 | 0.72 | 0.79 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.61 | 1.53 | 1.31 | 1.14 | 1.22 | |
| Quick Ratio (X) | 1.07 | 1.02 | 0.79 | 0.68 | 0.75 | |
| Inventory Turnover Ratio (X) | 2.03 | 2.18 | 2.30 | 1.93 | 2.11 | |
| Dividend Payout Ratio (NP) (%) | 8.65 | 7.45 | 8.80 | -68.31 | 9.88 | |
| Dividend Payout Ratio (CP) (%) | 7.45 | 6.43 | 6.54 | 29.01 | 8.16 | |
| Earnings Retention Ratio (%) | 91.35 | 92.55 | 91.20 | 168.31 | 90.12 | |
| Cash Earnings Retention Ratio (%) | 92.55 | 93.57 | 93.46 | 70.99 | 91.84 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 38,515.24 | 17,696.42 | 6,909.00 | 5,889.12 | 7,276.29 | |
| EV/Net Operating Revenue (X) | 4.76 | 2.49 | 1.27 | 1.38 | 1.76 | |
| EV/EBITDA (X) | 16.62 | 8.87 | 7.02 | 9.94 | 7.17 | |
| MarketCap/Net Operating Revenue (X) | 4.40 | 2.09 | 0.78 | 0.81 | 1.38 | |
| Retention Ratios (%) | 91.34 | 92.54 | 91.19 | 168.31 | 90.11 | |
| Price/BV (X) | 6.65 | 3.71 | 1.45 | 1.39 | 2.22 | |
| Price/Net Operating Revenue | 4.40 | 2.09 | 0.78 | 0.81 | 1.38 | |
| Earnings Yield | 0.04 | 0.08 | 0.12 | -0.01 | 0.10 |
07.01.2026
02.01.2026
19.12.2025
15.12.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL